A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine the tolerance and antiviral response of two different doses of atevirdine
mesylate (U-87201E) in symptomatic HIV-positive patients with CD4 counts of 50-350 cells/mm3,
who also take zidovudine (AZT).